Titanium and nitride oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population.
The aim of this study was to compare clinical outcome of a stainless-steel stent coated with titanium nitride oxide (TITANOX) and a paclitaxel-eluting stent (PES) in routine clinical practice represented by two prospective registries including all patients with de novo coronary artery disease treated exclusively with a TITANOX stent (n = 201) or with a PES (n = 204) between May 2003 and November 2004 (63% of all PCI patients). The primary endpoint of the study was major adverse cardiac events (MACE) at 30 days and 12 months. The TITANOX stent patients were more frequently (p = 0.011) treated for acute myocardial infarction and had more complex B- and C-type lesions (p = 0.004). The PES patients had longer (p < 0.001) total stent length. At 30 days, the rate of MACE was 0% and 4.9% for the TITANOX stent and PES groups, respectively (p = 0.001). A significant difference in target vessel revascularization (TVR) was seen in favor of the TITANOX stent (0% vs. 2.9% for PES; p = 0.014). This was mainly driven by stent thrombosis (n = 7). At 12 months, the difference in MACE was no longer significant (10.9% vs. 13.7%; p = 0.40), but the rate of myocardial infarction was lower in the TITANOX stent group (4.5% vs. 10.3%; p = 0.025). The rate of TVR (8% vs. 6.9%; p = 0.67) was similar between the two groups. In conclusion, both the TITANOX-coated stent and PES resulted in good clinical outcome with infrequent need for repeat interventions in the real-world setting of high-risk patients and complex coronary lesions.
Karjalainen
Pasi P
PP
Satakunta Central Hospital, Sairaalatie 3, Pori, 28100, Finland. pasi.karjalainen@satshp.fi
Ylitalo
Antti
A
Airaksinen
Juhani K E
JK
D000368:Aged; D020099:Coated Materials, Biocompatible; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization / Q000379:methods*; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use; D012042:Registries; D015607:Stents; D014025:Titanium; D016896:Treatment Outcome
D020099:Coated Materials, Biocompatible; C434243:titanium-nitride-oxide; D014025:Titanium; D017239:Paclitaxel